New CAR T-cell treatment for DIPG brain tumor
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new type of immunotherapy called B7H3 IL-7Ra CAR T-cells for children with DIPG, a tough-to-treat brain tumor. The treatment is given directly into the fluid around the brain using a special catheter, and the goal is to see if it's safe and if it can help fight the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with DIPG, a type of brain tumor in the brainstem, and have finished standard radiation therapy.
- You need to be between 1 and 18 years old.
- You must have a special catheter (like an Ommaya reservoir) placed in your brain to deliver the study treatment directly into the fluid around your brain.
- You should be able to perform most daily activities (score of 60 or higher on a function scale).
- Your major organs (liver, kidneys, heart, lungs) must be working well enough, and you must not have serious infections or other active cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR T cell therapy (BCB-276) for children and young adults with a type of brain tumor called DIPG. The therapy uses your own immune cells that are specially trained to attack the cancer.
This Phase 1 trial tests a personalized immune-cell treatment (CAR T) delivered directly in the brain-area space using a catheter. It may help children and young adults with hard-to-treat (recurrent or refractory) diffuse midline brain tumors like DIPG/DMG when standard options aren’t working.
This trial tests a new immune cell therapy (CAR T-cells) that targets a protein called CD70 found on some brain tumor cells. It is for children and young adults with newly diagnosed or recurrent high-grade glioma, including DIPG.
This trial tests a special immune-cell therapy (GD2 CAR T cells) made for pediatric brain tumor patients. It uses a planned treatment plan and monitoring to see if the therapy is safe and can work against the tumor.
This trial tests a new type of immune therapy called CAR T cells designed to find and attack a protein called B7-H3 on solid tumor cells. It's for children and young adults whose cancer came back or didn't respond to standard treatment.
This trial tests a new type of immune therapy (CAR T cells) that targets a protein called B7-H3 found on some brain tumors. It is for children and young adults with certain brain or spinal cord tumors that have come back after standard treatment, and aims to see if the treatment is safe and effective.
Hear when a new DIPG Brain Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.